Our cell line development timelines and innovation are unprecedented.

This is our focus, which is why we do it best.

Ultimately, we help companies get drugs to patients faster and more cost-effectively.

Selexis empowers scientists and biopharmaceutical companies around the world to realize the full potential of their work.

Cell Line Development

Selexis SA, A JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.

SUREtechnology Platform

Our global partners are utilizing Selexis gene technologies to advance more than 115 drug products in clinical development and the manufacture of five commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.

RECENT AND UPCOMING EVENTS

BioKorea, Seoul | April 17 – 19, 2019
Venue of international exchange institution “COEX”

ESACT, Copenhagen | May 5 – 8, 2019
Bella Center

Genome Editing USE Congress 2019, Boston | May 14 – 15, 2019
Hynes Convention Center

BIO 2019 International Convention, Philadelphia | June 3 – 6, 2019
Pennsylvania Convention Center

Cell  Line Development and Engineering/ BPI, San Francisco | June 18 – 20, 2019
Park Central Hotel

BioPharma Expo JP, Tokyo | July 3 – 5, 2019
Tokyo Big Sight

JAACT 2019, Kagoshima | July 18 – 19, 2019
Tsukuba International Congress Center (Epochal Tsukuba)

FULL CALENDAR AND ADDITIONAL DETAILS

FEATURED CONTENT

Selexis Corporate Overview Q1 2019

Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.

Learn More

We are Social

With the ability to express any recombinant protein, including difficult-to-express proteins, Selexis is proud to have partnered global biopharmaceutical companies, supporting the development of innovative therapies across a range of diseases